ESMO Open最新文献

{"title":"Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE)","authors":"M. Ueno ,&nbsp;C. Morizane ,&nbsp;M. Ikeda ,&nbsp;M. Ozaka ,&nbsp;F. Nagashima ,&nbsp;T. Kataoka ,&nbsp;J. Mizusawa ,&nbsp;A. Ohba ,&nbsp;S. Kobayashi ,&nbsp;H. Imaoka ,&nbsp;A. Kasuga ,&nbsp;N. Okano ,&nbsp;Y. Nagasaka ,&nbsp;M. Sasaki ,&nbsp;J. Furuse ,&nbsp;T. Okusaka","doi":"10.1016/j.esmoop.2024.103919","DOIUrl":"10.1016/j.esmoop.2024.103919","url":null,"abstract":"<div><h3>Background</h3><div>Although cisplatin plus gemcitabine and other combinations have improved the survival of advanced biliary tract cancer (BTC), high unmet medical needs remain. This study aimed to assess the efficacy and safety of nivolumab plus lenvatinib in the second-line treatment for advanced BTC.</div></div><div><h3>Patients and methods</h3><div>Nivolumab (240 mg) was administered biweekly. Phase I determined the recommended phase II dose of lenvatinib (20 mg or 14 mg). In phase II, the primary endpoint was the objective response rate (ORR). Secondary endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. The planned sample size was 32 patients with a power of 80%, a one-sided alpha error of 5%, threshold ORR of 10%, and expected ORR of 30%.</div></div><div><h3>Results</h3><div>In phase I, the recommended dose of lenvatinib was determined to be 20 mg in six patients, with one dose-limiting toxicity (myocarditis). In phase II, we enrolled 26 patients. ORR, DCR, and median OS and PFS were 9.4% [90% confidence interval (CI) 2.6% to 22.5%], 53.1% (95% CI 34.7% to 70.9%), and 6.4 months (95% CI 4.9-9.7 months) and 2.5 months (95% CI 1.5-4.1 months), respectively. No response was observed <em>in patients with</em> the usage of antibiotics. The grade 3 or 4 adverse events were hypertension (59.4%) and biliary tract infection (37.5%). Rash (28.1%) and hypothyroidism (21.9%) were observed as immune-mediated adverse events of any grade.</div></div><div><h3>Conclusions</h3><div>Nivolumab plus lenvatinib had a manageable safety in advanced BTC, but its efficacy in the second-line treatment was limited.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103919"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142357133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review","authors":"D. Prost ,&nbsp;S. Iseas ,&nbsp;M. Gatineau ,&nbsp;J. Adam ,&nbsp;S. Cavalieri ,&nbsp;C. Bergamini ,&nbsp;L. Licitra ,&nbsp;É. Raymond","doi":"10.1016/j.esmoop.2024.103722","DOIUrl":"10.1016/j.esmoop.2024.103722","url":null,"abstract":"<div><h3>Background</h3><div>Salivary gland cancers are infrequent and pose a challenge owing to their histological diversity and varied clinical behavior, making the selection of optimal systemic treatments for advanced or recurrent stages difficult. This systematic review aims to assess overall survival outcomes and systemic treatment responses across four types of salivary cancers.</div></div><div><h3>Methods</h3><div>A PubMed and Google Scholar search identified studies involving initially advanced or relapsed cases undergoing systemic treatment. Studies with clear, individualized data on treatment responses and outcomes were selected based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Of the 723 studies screened, 44 met our inclusion criteria.</div></div><div><h3>Results</h3><div>A total of 426 cases of recurrent/metastatic salivary gland cancer, mostly salivary duct carcinoma (SDC; <em>n</em> = 219) and adenoid cyst carcinoma (ACC; <em>n</em> = 167), were included. Histomolecular markers were heavily associated with histology, with <em>HER2</em> overexpression and androgen receptor nuclear expression typically found in SDC and adenocarcinoma not otherwise specified cases and KIT overexpression only in ACC. The response rates were associated with specific receptor blockage, with trastuzumab plus chemotherapy, and bicalutamide being the most effective (overall response rate 80% and 42.8%, respectively). Moreover, the response to treatment positively influenced overall survival (responders 38 versus non-responders 18.7 median months; <em>P</em> &lt; 0.001). In this retrospective analysis of a particular cohort, survival outcomes per histology types showed that anti-human epidermal growth factor receptor 2 therapy was more effective for SDC, while chemotherapy was more effective for ACC.</div></div><div><h3>Conclusion</h3><div>Systemic treatments contribute to the survival of patients with salivary gland cancer at relapsed or newly advanced stages. The response to treatment is heavily influenced by histological subtype and treatment specificity.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103722"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"58P NSCLC genomic complexity: Insights from comprehensive molecular profiling in the era of precision medicine","authors":"P. Paliwal,&nbsp;V. Bhatia,&nbsp;S. Sharma,&nbsp;B. Bansal,&nbsp;S. K,&nbsp;A. Bhandari,&nbsp;S. Rana,&nbsp;S. Ahlawat","doi":"10.1016/j.esmoop.2024.103803","DOIUrl":"10.1016/j.esmoop.2024.103803","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103803"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2O Prostate cancer BRCA mutation prediction using multiple-instance learning and histopathology","authors":"C. Macarro ,&nbsp;P. Cresta Morgado ,&nbsp;S. Simonetti ,&nbsp;D. Navarro ,&nbsp;H. Alatoom ,&nbsp;C. Zatse ,&nbsp;D. Olmos ,&nbsp;P.G. Nuciforo ,&nbsp;A. Vivancos ,&nbsp;R. Olivera-Salguero ,&nbsp;T. Pascual ,&nbsp;J. Carles Galceran ,&nbsp;E. Castro ,&nbsp;J. Mateo ,&nbsp;R. Perez Lopez","doi":"10.1016/j.esmoop.2024.103748","DOIUrl":"10.1016/j.esmoop.2024.103748","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103748"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142530470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"6P Diagnostic accuracy of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry slides: A systematic review and meta-analysis","authors":"D. Arruda Navarro Albuquerque ,&nbsp;M. Trotta Vianna ,&nbsp;A. Vasiliu ,&nbsp;E.H. Cunha Neves Filho","doi":"10.1016/j.esmoop.2024.103752","DOIUrl":"10.1016/j.esmoop.2024.103752","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103752"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142530476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"68P ESR1 gene mutation in hormone receptor (HR)-positive metastatic breast cancers: An NGS-based exploratory study on Indian population","authors":"S. Shanthala ,&nbsp;U. Amirtham ,&nbsp;L.A. Jacob ,&nbsp;C. Karunakaran ,&nbsp;P.P.P. Bapsy","doi":"10.1016/j.esmoop.2024.103812","DOIUrl":"10.1016/j.esmoop.2024.103812","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103812"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"71P When neighbors play a role: The importance of interacting proteins in the tumorigenic effect of cancer driver genes","authors":"M. Carrolo ,&nbsp;M. Vital ,&nbsp;J. Miranda ,&nbsp;A. Quintela ,&nbsp;F. Pinto","doi":"10.1016/j.esmoop.2024.103815","DOIUrl":"10.1016/j.esmoop.2024.103815","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103815"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"61P Unveiling the distinctive molecular, clinical, and prognostic features of infant acute myeloid leukemia: An analysis study of pediatric AML datasets from the Children's Oncology Group","authors":"Y. Tao","doi":"10.1016/j.esmoop.2024.103806","DOIUrl":"10.1016/j.esmoop.2024.103806","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103806"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"16P The role of systemic immunity in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy","authors":"C. Molinari ,&nbsp;J. Bulgarelli ,&nbsp;F. Rebuzzi ,&nbsp;R. Camara ,&nbsp;V. Kokala Dimitropoulou ,&nbsp;E. Petracci ,&nbsp;J. Ewald ,&nbsp;D. Prascevic ,&nbsp;P. Ulivi ,&nbsp;M. Canale ,&nbsp;M. Monti ,&nbsp;S. Tamberi ,&nbsp;A. Derventzi","doi":"10.1016/j.esmoop.2024.103762","DOIUrl":"10.1016/j.esmoop.2024.103762","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103762"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"50P Integrin-fibronectin interplay is a pivotal biological and clinical determinant in papillary thyroid carcinoma","authors":"D. Rocco,&nbsp;M. Vitale","doi":"10.1016/j.esmoop.2024.103795","DOIUrl":"10.1016/j.esmoop.2024.103795","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103795"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}